Claritev reported Q4 2025 revenue of USD 246.6 million (+6.2%) and a net loss of USD 80.6 million, with adjusted EBITDA of USD 151.3 million. Net cash provided by operating activities was USD 66.3 million and free cash flow was USD 36.4 million; Claritev ended Q4 with USD 16.8 million of unrestricted cash and cash equivalents. During Q4, Claritev processed USD 47.2 billion in claim charges and identified potential medical cost savings of about USD 6.4 billion. For FY 2025, Claritev posted revenue of USD 965.4 million (+3.7%), a net loss of USD 284.3 million, and adjusted EBITDA of USD 602.6 million. Operating cash flow was USD 117.3 million and free cash flow was a loss of USD 12.3 million; FY claim charges processed were USD 179.8 billion with potential medical cost savings of about USD 25 billion. Claritev introduced FY 2026 guidance calling for revenue of USD 980 million to USD 1 billion, adjusted EBITDA of USD 605 million to USD 615 million, capital expenditures of USD 160 million to USD 170 million, an effective tax rate of 24% to 28%, and free cash flow of USD 0 million to USD 10 million. The board also approved a five-year share repurchase program of up to USD 75 million (capped at USD 20 million per calendar year) running from January 1, 2026 through December 31, 2030. Management highlighted 2025 as a return to top-line revenue growth, a rebrand to Claritev, expansion into vertical markets, new solutions and partnerships, record bookings, and a migration of its technology foundation, while the CFO said the company expects to return to positive free cash flow in 2026 and prioritize organic growth, opportunistic debt reduction, and M&A.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Claritev Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260223139964) on February 23, 2026, and is solely responsible for the information contained therein.
Comments